V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Roivant Sciences Executive Compensation (FY24)

ROIV · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Matthew Gline
Median of the other named officers
$4,693,938
5 officers, excluding the chief executive
Latest say-on-pay support
=
September 10, 2025
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Roivant Sciences brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (DEF 14A): July 29, 2026
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Roivant Sciences brief$1,500Get the executive brief
Velarion Member, one year
240 figures on this page: 238 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Matthew Gline: $738,189 → $163,293,744

Frequently asked questions

Answers drawn from the data on this page.
Who is Roivant Sciences' chief executive and what were they paid?
Total compensation for Matthew Gline, Chief Executive Officer, came to $163,293,744 in fiscal 2024. Gline's total was up from the $738,189 reported for fiscal 2023.
What was Roivant Sciences' say-on-pay result?
For fiscal 2024, shareholders backed the say-on-pay proposal with 60.9% of votes cast for or against in favor at the meeting held September 10, 2025.
Which companies are in Roivant Sciences' peer group?
The disclosed peer group names ACADIA Pharmaceuticals Inc., Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Arcutis Biotherapeutics, Inc. and Ascendis Pharma, Inc., among others.
What is Roivant Sciences' chief executive pay ratio?
The company reported a chief executive pay ratio of 518:1 for fiscal 2024, against median employee compensation of $315,444.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Matthew Gline
Chief Executive Officer
◇◇—◇——◇◇
Mayukh Sukhatme
President and Chief Investment Officer
◇◇—◇——◇◇
Eric Venker
President and Immunovant CEO
◇◇—◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard Pulik
Chief Financial Officer
◇◇◇◇——◇◇
Rakhi Kumar
Former Chief Accounting Officer
◇◇◇◇——◇◇
Matthew Gline
Chief Executive Officer
◇—————◇◇
Eric Venker
President and Immunovant CEO
◇—————◇◇
Mayukh Sukhatme
President and Chief Investment Officer
◇—————◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mayukh Sukhatme
President and Chief Investment Officer
◇◇◇———◇◇
Matthew Gline
Chief Executive Officer
◇◇◇———◇◇
Eric Venker
President and Immunovant CEO
◇◇◇◇——◇◇
Rakhi Kumar
Former Chief Accounting Officer
Departed during or after this year
◇◇◇◇——◇◇
Richard Pulik
Chief Financial Officer
◇◇◇◇——◇◇
Jennifer Humes
Chief Accounting Officer
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Eric VenkerOPTION◇——◇—◇◇
Eric VenkerRSU◇——◇——◇
Jennifer HumesRSU◇——◇——◇
Jennifer HumesOPTION◇——◇—◇◇
Matthew GlineRSU◇——◇——◇
Matthew GlinePSU◇◇——◇—◇
Mayukh SukhatmeRSU◇——◇——◇
Mayukh SukhatmePSU◇◇——◇—◇
Rakhi KumarOPTION◇——◇—◇◇
Rakhi KumarRSU◇——◇——◇
Richard PulikOPTION◇——◇—◇◇
Richard PulikRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Rakhi KumarOption◇—◇4/21/2034
RSU◇◇——
Option◇—◇5/1/2031
Option◇—◇4/19/2033
Option◇—◇4/19/2032
RSU◇◇——
RSU◇◇——
Mayukh SukhatmeOption◇—◇5/1/2031
RSU◇◇——
PSU◇◇——
Option◇—◇5/19/2029
Option◇—◇4/19/2032
Eric VenkerOption◇—◇5/1/2031
Option◇—◇5/1/2031
Option◇—◇4/19/2032
RSU◇◇——
Option◇—◇7/25/2034
RSU◇◇——
Matthew GlineOption◇—◇5/1/2031
PSU◇◇——
Option◇—◇4/19/2032
Option◇—◇5/1/2031
RSU◇◇——
RSU◇◇——
Richard PulikOption◇—◇10/19/2031
RSU◇◇——
Option◇—◇4/21/2034
RSU◇◇——
RSU◇◇——
Option◇—◇4/19/2032
Option◇—◇4/19/2033
Jennifer HumesOption◇—◇3/19/2035
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Eric Venker
President and Immunovant CEO · Employment agreement · citing a 2021 filing
Severance multiple◇
Change-in-control trigger◇
Equity acceleration on change in control◇
Benefits continuation◇
Clawback◇
Mayukh Sukhatme
President and Chief Investment Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Rakhi Kumar
Former Chief Accounting Officer · Employment agreement · citing a 2024 filing
Severance multiple◇
Change-in-control trigger◇
Equity acceleration on change in control◇
Benefits continuation◇
Clawback◇
Richard Pulik
Chief Financial Officer · Employment agreement · citing a 2024 filing
Benefits continuation◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ilan Oren
◇◇◇———◇
Melissa Epperly
◇◇◇———◇
Daniel Gold
◇◇◇———◇
Meghan FitzGerald
◇◇◇———◇
Keith Manchester
◇◇◇———◇
James C. Momtazee
◇◇◇———◇
Mayukh Sukhatme and Matthew Gline served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as RSUs and Stock Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Amicus Therapeutics, Inc. FOLD
  • Apellis Pharmaceuticals, Inc. APLS
  • Arcutis Biotherapeutics, Inc. ARQT
  • Ascendis Pharma, Inc. ASND
  • Axsome Therapeutics, Inc. AXSM
  • Blueprint Medicines Corporation BPMC
  • BridgeBio Pharma, Inc. BBIO
  • Cerevel Therapeutics Holdings, Inc. CERE
  • CRISPR Therapeutics, Inc. CRSP
  • Denali Therapeutics Inc. DNLI
  • Exelixis, Inc. EXEL
  • Halozyme Therapeutics, Inc. HALO
  • ImmunoGen, Inc. IMGN
  • Incyte Corporation INCY
  • Intra-Cellular Therapies, Inc. ITCI
  • Ionis Pharmaceuticals, Inc. IONS
  • Jazz Pharmaceuticals, Inc. JAZZ
  • Karuna Therapeutics, Inc. KRTX
  • MoonLake Immunotherapeutics MLTX
  • Neurocrine Biosciences Inc. NBIX
  • Revolution Medicines, Inc. RVMD
  • Sarepta Therapeutics, Inc. SRPT
  • United Therapeutics Corporation UTHR
  • Vaxcyte, Inc. PCVX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024September 10, 2025=◇◇◇
2023September 10, 2024=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Matthew Gline (Chief Executive Officer), FY2024 total compensation $163,293,744 (base salary $725,000) [exec_comp, SEC accession 0001140361-25-027846, filed 2025-07-29]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Roivant Sciences files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Roivant Sciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Roivant Sciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Roivant Sciences recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Roivant Sciences' disclosed peer group is defensible, who names Roivant Sciences back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
240 figures on this page: 238 cited to the filing that reported them, 2 calculated from figures it prints.
238 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001140361-26-029955
    Director Compensation
  2. 0001140361-25-034711
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  3. 0001140361-24-041188
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  4. 0001140361-24-034423
    Summary Compensation Table
  5. 0001140361-23-037044
    Summary Compensation Table
  6. 0001140361-25-027846
    Compensation Discussion and Analysis · Director Compensation Table for Fiscal 2024 · Outstanding Equity Awards at 2024 Fiscal Year End · Outstanding Equity Awards at Fiscal Year End · and 1 more section
  7. 0001193125-21-162191
    EX-10.11
  8. 0001140361-24-036642
    EX-10.26 · EX-10.27
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Roivant Sciences executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/ROIV (accessed 2026).
Short form: data: Velarion

The Roivant Sciences brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Roivant Sciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Roivant Sciences discloses

The companies named in ROIV's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Amicus Therapeutics, Inc.Apellis Pharmaceuticals, Inc.Arcutis Biotherapeutics, Inc.Axsome Therapeutics, Inc.Blueprint Medicines CorporationBridgeBio Pharma, Inc.Cerevel Therapeutics Holdings, Inc.CRISPR Therapeutics, Inc.Denali Therapeutics Inc.Exelixis, Inc.Halozyme Therapeutics, Inc.ImmunoGen, Inc.Incyte CorporationIntra-Cellular Therapies, Inc.Ionis Pharmaceuticals, Inc.Jazz Pharmaceuticals, Inc.Karuna Therapeutics, Inc.MoonLake ImmunotherapeuticsNeurocrine Biosciences Inc.Revolution Medicines, Inc.Sarepta Therapeutics, Inc.United Therapeutics CorporationVaxcyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy